The Latest Breaking News from FDA

Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Jul 21, 2022

House seeks to protect contraception after Roe changes - Roll Call

Eight Republicans crossed the aisle to join every House Democrat on a bill that would codify the federal right to contraception.

Roll Call · Jul 21, 2022

TikTok’s ‘Pink Sauce’ Is Appalling The Internet When Did We Stray So Far From The Path Of God

It's the EZ Squirt of our generation.

Pedestrian.tv · Jul 21, 2022

Experts still torn on throat swabbing

Other countries' health bureaus have advised the public to throat-swab when taking at-home tests, but not the US

Salon · Jul 20, 2022

Abbott reports strong earnings despite infant formula crisis

Abbott Laboratories reported strong earnings Wednesday, despite spending recent months responding to criticism over problems that led to the shutdown of one of its infant formula-producing plants.

Chicago Tribune · Jul 20, 2022

How canine heart disease was tied to grain-free dog food

In 2018, the FDA began investigating whether the increasing popularity of grain-free dog foods had led to a sudden rise in a potentially fatal heart disease in dogs

The Independent UK · Jul 20, 2022

The Daily Biotech Pulse: CDC AdComm Backs Novavax COVID-19 Vaccine, European Approval For PTC Therapeutics' Gene Therapy, Merck's Keytruda Flunks In Head, Neck Cancer Study

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Jul 20, 2022

Get fourth COVID booster now, or wait? CDC says get the shot now, but many hesitate

About 70% of Americans 50 and older who got a first booster shot — and nearly as many of those 65 and older — haven’t gotten their second booster dose, the CDC says.

Chicago Sun-Times · Jul 20, 2022

Skittles "unfit" for humans: lawsuit

When Americans eat Skittles, are they tasting more than just the rainbow?

Salon · Jul 19, 2022

Recap of Tuesday's Biotech Catalysts - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy.

Benzinga · Jul 19, 2022